Charlie Lees
3y ago
3 hot off the press pharma stories about new molecules for IBD
• upadacitinib gains MHRA approval for Crohn's disease
• filgotinib fails to meet key Crohn's endpoints in DIVERSITY
• Takeda complete deal with Nimbus to acquire promising TYK2 molecule
Links below in 🧵
1/5
Charlie Lees
3y ago
Upadacitinib (Rinvoq - Abbvie) receives its first global licence for Crohn's disease
MHRA grants approval for use in the UK
NICE and SMC approvals should follow soon in the UK
2/5
Charlie Lees
3y ago
DIVERSITY enrolled 1374 patients with Crohn's disease
The press release notes that not all key primary outcomes were met
Galapagos decides not to pursue filgotinib for this indication
Does not affect use in UC
3/5
Charlie Lees
3y ago
Takeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary
TAK-279 - a highly selected oral TYK2 inhibitor - being pursued in psoriasis, inflammatory bowel disease and lupus
4/5
Charlie Lees
3y ago
I'll write more about what these other developments mean in Atomic IBD next week
5/5